28.39
price down icon3.60%   -1.06
pre-market  プレマーケット:  28.39  
loading
前日終値:
$29.45
開ける:
$29.03
24時間の取引高:
483.91K
Relative Volume:
0.47
時価総額:
$3.69B
収益:
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-0.21%
1か月 パフォーマンス:
+3.27%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
Value
$27.80
$29.03
1週間の範囲:
Value
$26.25
$30.06
52週間の値動き範囲:
Value
$12.30
$37.99

Metsera Inc Stock (MTSR) Company Profile

Name
名前
Metsera Inc
Name
セクター
Healthcare (1164)
Name
電話
(212) 784-6595
Name
住所
3 WORLD TRADE CENTER, NEW YORK
Name
職員
98
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
MTSR's Discussions on Twitter

MTSR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
MTSR
Metsera Inc
28.39 3.69B 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.41 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
538.11 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.13 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
546.04 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
240.99 28.51B 3.81B -644.79M -669.77M -6.24

Metsera Inc Stock (MTSR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-25 開始されました BofA Securities Buy
2025-02-25 開始されました Evercore ISI Outperform
2025-02-25 開始されました Guggenheim Buy

Metsera Inc (MTSR) 最新ニュース

pulisher
Jun 17, 2025

Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i’s Positive Phase 1 Results - MSN

Jun 17, 2025
pulisher
Jun 13, 2025

Cantor Fitzgerald reiterates Metsera stock rating on strong MET-233i results - Investing.com Nigeria

Jun 13, 2025
pulisher
Jun 12, 2025

Promising Results Of Amylin Analogs In Obesity: Metsera Case Review (NASDAQ:MTSR) - Seeking Alpha

Jun 12, 2025
pulisher
Jun 12, 2025

Cantor Fitzgerald Predicts Metsera FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

13 Biotech Stocks with Huge Upside Potential - Insider Monkey

Jun 11, 2025
pulisher
Jun 11, 2025

RFK Axes CDC Vaccine Advisors; Metsera’s Weight Loss Win; FDA Supports CGT - BioSpace

Jun 11, 2025
pulisher
Jun 11, 2025

Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire

Jun 11, 2025
pulisher
Jun 11, 2025

Metsera Shows Rising Price Performance With Jump To 92 RS Rating - Investor's Business Daily

Jun 11, 2025
pulisher
Jun 11, 2025

Metsera (NASDAQ:MTSR) Price Target Raised to $62.00 at Guggenheim - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Metsera (NASDAQ:MTSR) Shares Gap Up Following Analyst Upgrade - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Metsera stock extends gains on obesity drug data (MTSR:NASDAQ) - Seeking Alpha

Jun 10, 2025
pulisher
Jun 10, 2025

Metsera’s obesity candidate ‘comparable to leading GLP-1-based medicines’ - The Pharma Letter

Jun 10, 2025
pulisher
Jun 10, 2025

Metsera price target raised to $62 from $56 at Guggenheim - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Metsera CEO to Present Obesity Drug Pipeline at Goldman Sachs Healthcare Conference | MTSR Stock News - Stock Titan

Jun 10, 2025
pulisher
Jun 10, 2025

Metsera Hits New High As Obesity Pipeline Gains Weight - RTTNews

Jun 10, 2025
pulisher
Jun 10, 2025

Metsera Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily

Jun 10, 2025
pulisher
Jun 09, 2025

Metsera chasing best-in-class profile with amylin program - biocentury.com

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera reports promising Phase 1 trial results for obesity treatment By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i - GlobeNewswire

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera’s Amylin Analog Stars In Obesity Phase I - insights.citeline.com

Jun 09, 2025
pulisher
Jun 09, 2025

Obesity treatment startup Metsera rises on positive trial results - Sherwood News

Jun 09, 2025
pulisher
Jun 09, 2025

metsera reports positive phase 1 trial results for obesity drug - Investing.com Australia

Jun 09, 2025
pulisher
Jun 09, 2025

Obesity Newcomer Metsera Enters The Ring With A Punch — And A Big Stock Jump - Investor's Business Daily

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter Explodes By Stocktwits - Investing.com India

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera rises as experimental weight-loss drug shows promise in small early-stage trial - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med - MedCity News

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data - Benzinga

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera obesity monotherapy data ‘looks competitive,’ says BofA - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter Explodes - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera shares climb on early data for amylin-targeting obesity shot - BioPharma Dive

Jun 09, 2025
pulisher
Jun 09, 2025

Warner Bros. Discovery, Metsera, eToro Group And Other Big Stocks Moving Higher On Monday - Benzinga

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera's Phase 1 Trial of MET-233i Shows Weight Reduction With no Severe Adverse Events - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera Shares Rise as Monthly Weight Loss Injection Shaves Over 8% Body Weight at 36 Weeks - BioSpace

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera’s drug shows potential in early clinical trial - statnews.com

Jun 09, 2025
pulisher
Jun 09, 2025

metsera reports positive phase 1 trial results for obesity drug By Investing.com - Investing.com Canada

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera shares soar on positive amylin candidate trial results By Investing.com - Investing.com Nigeria

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera shares soar on positive amylin candidate trial results - Investing.com Australia

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera announces topline data from Phase 1 trial of MET-233i - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera, Inc. Reports Positive Phase 1 Trial Results - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Obesity Startup Metsera Shares Rise on Early-Stage Trial Results - Bloomberg.com

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera reports promising Phase 1 trial results for obesity treatment - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera’s amylin drug shows early potential for substantial weight loss - statnews.com

Jun 09, 2025
pulisher
Jun 09, 2025

Weight Loss Drug Shows 8.4% Reduction in Phase 1 Trial, Monthly Dosing Success | MTSR Stock News - Stock Titan

Jun 09, 2025
pulisher
Jun 05, 2025

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association® - The Manila Times

Jun 05, 2025
pulisher
Jun 05, 2025

Metsera to Present New Research Highlighting the Breadth - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association - TradingView

Jun 05, 2025
pulisher
Jun 05, 2025

Next-Gen Monthly Obesity Drug Shows Promise: Metsera to Present Breakthrough Clinical Data at ADA 2025 - Stock Titan

Jun 05, 2025
pulisher
Jun 02, 2025

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership - insights.citeline.com

Jun 02, 2025

Metsera Inc (MTSR) 財務データ

Metsera Inc (MTSR) の財務データはありません。詳細については、他の銘柄を確認してください。

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Metsera Inc (MTSR) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
BERNS PAUL L
Director
Feb 03 '25
Buy
18.00
789,998
14,219,964
8,313,680
ARCH Venture Partners XII, LLC
10% Owner
Feb 03 '25
Buy
18.00
2,222,222
39,999,996
18,503,128
$20.52
price up icon 1.08%
$35.59
price down icon 2.14%
$22.61
price down icon 7.90%
$96.95
price down icon 0.87%
$110.05
price up icon 0.05%
biotechnology ONC
$240.99
price down icon 1.83%
大文字化:     |  ボリューム (24 時間):